No Data
Pulse Biosciences Is on Track for IDE Study of PFA Tech This Year
Pulse Biosciences Announces Nanosecond PFA 360° Cardiac Catheter Study Results, 92.4% Success At 3 Months In Initial 30 AF Patients; IDE Study Planned For 2025
Pulse Biosciences Updates Investors on Cardiac Innovations
Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Multiple Presentations at the AF Symposium
Pulse Biosciences Pickes Former Boston Scientific Exec as New CEO
Express News | Pulse Biosciences, Inc. Appoints Paul Laviolette as Chief Executive Officer
